国际肿瘤学杂志

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (8): 535-538.doi: 10.3760/cma.j.issn.1673-422X.2018.09.005

• 论著 • 上一篇    下一篇

康莱特注射液联合NP方案化疗对晚期 NSCLC患者免疫状态、炎症因子 及生命质量的影响

李超,陈俊花,吴静   

  1. 618000 四川省德阳市人民医院肿瘤科
  • 出版日期:2018-09-08 发布日期:2018-11-15
  • 通讯作者: 李超 E-mail:445596048@qq.com

Effects of Kanglaite injection combined with NP chemotherapy for immune status, inflammatory factors and quality of life of patients with advanced NSCLC

Li Chao, Chen Junhua, Wu Jing   

  1. Department of Oncology, People′s Hospital of Deyang City of Sichuan Province, Deyang 618000, China
  • Online:2018-09-08 Published:2018-11-15
  • Contact: Li Chao E-mail:445596048@qq.com

PDF

644

摘要： 目的探讨康莱特注射液联合NP方案（长春瑞滨+顺铂）化疗对晚期非小细胞肺癌（NSCLC）患者免疫状态、炎症因子及生命质量的影响。方法选取2014年6月至2017年1月我院收治的晚期NSCLC患者106例，按照入院单双号分为对照组和观察组，每组53例。对照组予以NP方案化疗，观察组采用康莱特注射液+NP方案化疗。观察两组患者的免疫状态、炎症因子及生命质量变化，并进行统计比较。结果治疗后观察组患者CD3+（62.64%±3.96%∶54.08%±7.19%）、CD4+（37.10%±5.09%∶29.22%±6.38%）、CD4+/CD8+（1.96±0.62∶1.12±0.39）和自然杀伤细胞（22.45%±5.92%∶16.37%±6.13%）等免疫学指标明显高于对照组（t=7.592，P＜0.001；t=7.029，P＜0.001；t=8.349，P＜0.001；t=5.194，P＜0.001）。治疗后，观察组患者白细胞介素6［（80.56±10.27）ng/L∶（102.87±14.58）ng/L］、肿瘤坏死因子α［（8.35±2.73）ng/L∶（15.69±3.14）ng/L］和C反应蛋白［（9.18±2.38）mg/L∶（13.84±2.92）mg/L］水平显著低于对照组，差异均有统计学意义（t=9.107，P＜0.001；t=12.843，P＜0.001；t=9.006，P＜0.001）。治疗后观察组Karnofsky功能状态评分改善情况优于对照组（Z=3.133，P=0.002）。观察组治疗有效率显著高于对照组（58.49%∶35.85%），差异有统计学意义（χ2=5.451，P=0.020）。结论康莱特注射液联合NP方案化疗治疗晚期NSCLC疗效肯定，可有效改善患者的免疫状态，降低炎症反应，提高生命质量。

关键词: 癌, 非小细胞肺, 药物疗法, 免疫, 炎症, 生活质量, 康莱特注射液

Abstract: ObjectiveTo investigate the effect of Kanglaite injection combined with NP (navelbine + cisplatin) chemotherapy for immune status, inflammatory factors and quality of life of patients with advanced nonsmall cell lung cancer (NSCLC). MethodsA total of 106 patients with advanced NSCLC admitted to our hospital from June 2014 to January 2017 were  divided into control group and observation group according to admission even and odd numbers, and 53 cases in each group. The patients in control group received chemotherapy with NP regimen, and the patients in observation group received Kanglaite injection + NP regimen chemotherapy. The immune status, inflammatory factors and quality of life of the patients in the two groups were observed and compared statistically. ResultsAfter treatment, the immune indexes including CD3+ (62.64%±3.96% vs. 54.08%±7.19%), CD4+ (37.10%±5.09% vs. 29.22%±6.38%), CD4+/CD8+ (1.96±0.62 vs. 1.12±0.39) and natural kill cells (22.45%±5.92% vs. 16.37%±6.13%) of observation group were apparently higher than those of control group (t=7.592, P＜0.001; t=7.029, P＜0.001; t=8.349, P＜0.001; t=5.194, P＜0.001). After treatment, the levels of interleukin6 ［(80.56±10.27) ng/L vs. (102.87±14.58) ng/L］, tumor necrosis factorα ［(8.35±2.73) ng/L vs. (15.69±3.14) ng/L］, Creactive protein ［(9.18±2.38) mg/L vs. (13.84±2.92) mg/L］ of observation group were significantly lower than those of control group (t=9.107, P＜0.001; t=12.843, P＜0.001; t=9.006, P＜0.001). The improved condition of Karnofsky performance status score of observation group was significantly better than that of control group (Z=3.133, P=0.002). The effective rate of observation group was significantly higher than that of control group (58.49% vs. 35.85%), with significant difference (χ2=5.451, P=0.020). ConclusionThe efficacy of Kanglaite injection combined with NP regimen in the treatment of advanced NSCLC is positive, which can effectively improve the immune status of patients, reduce inflammatory reaction and improve quality of life.

Key words: Carcinoma, nonsmallcell lung, Drug therapy, Immunity, Inflammation, Quality of life, Kanglaite injection